Which of the following statements is true about Pletal (cilostazol)?

Pletal (cilostazol) is primarily recognized for its role in treating intermittent claudication, which is characterized by pain and cramping in the legs due to inadequate blood flow during exercise. Cilostazol works by inhibiting phosphodiesterase III, leading to increased levels of cyclic AMP, which results in vasodilation and reduced platelet aggregation. This mechanism improves blood flow and alleviates symptoms associated with intermittent claudication, making the statement regarding its use for symptomatic treatment accurate.

In contrast, the other statements do not accurately represent the properties or uses of cilostazol. It is not a direct thrombin inhibitor, nor is it classified as an irreversible antiplatelet agent. While cilostazol does have some effects on platelets, it functions differently from traditional antiplatelet medications that cause permanent inhibition of platelet activity. Additionally, cilostazol is metabolized by the liver, and while renal function may influence its metabolism, specific renal dose adjustments are generally not a requirement like they are for many other drugs.